Abstracts

1034 – Pediatric ART Interruptions Transiently Raise HIV DNA Without Large Changes to Long-Term Reservoirs

Background To inform pediatric HIV persistence inclusive of scenarios where antiretroviral therapy (ART) usage may not be completely suppressive, we sought to elucidate reservoir dynamics with and without occasional HIV RNA viremia. Methods In Kenyan children living with HIV who initiated ART between 1-12 months of age (median 3 months), we measured HIV RNA and HIV DNA…

1188 – HIV Recent Infection Surveillance Adds 17 Minutes to HIV Testing Services per Patient With HIV

Background Cost and implementation complexity of using HIV-1 Asanté rapid recency assays (ARRA) in routine HIV Testing Services (HTS) are previously cited concerns in scaling and sustaining HIV-1 recent infection surveillance (HRIS) in settings where workload of health care workers (HCW) remains high. We measured the additional time spent on facility-based and laboratory-based HRIS by…

1015 – Long-Acting Cabotegravir/Rilpivirine in Pregnancy

Background Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) is a novel injectable antiretroviral therapy approved for virologically suppressed individuals with HIV-1. Data on the safety, efficacy, and outcomes for individuals receiving LA-CAB/RPV during pregnancy are limited. We evaluated HIV viral suppression, perinatal, and neonatal outcomes in pregnant persons with HIV-1 receiving LA-CAB/RPV. This is the first case…

1094 – Long-Term Sequelae of Mpox: A Cohort Study in 2 Tertiary Centers

Background The global outbreak of clade IIb Mpox Virus (MPXV) caused significant morbidity, particularly among men who have sex with men and persons living with HIV (PLWH). The medical, mental, and socioeconomic consequences of mpox remain unknown. Methods We conducted a retrospective, longitudinal study using chart reviews and telephone questionnaires to evaluate the long-term effects…

1010 – TFV-DP Concentrations in PBMCs and Safety of Daily Directly Observed F/TDF PrEP During Pregnancy

Background Intracellular tenofovir diphosphate (TFV-DP) concentrations from F/TDF PrEP in dried blood spots are ~30-50% lower during pregnancy, but data on TFV-DP levels achieved in peripheral blood mononuclear cells (PBMCs), the clinically relevant site for HIV prevention, are limited. We evaluated the effect of pregnancy on TFV-DP levels in PBMCs and birth and infant growth…

1096 – Impact of COVID-19 Healthcare Disruptions on ART Initiation and Viral Suppression: US, 2018-2021

Background Rapidly initiating antiretroviral therapy (ART) and achieving viral suppression (VS) among newly diagnosed people with HIV (PWH) are cornerstones of HIV care. COVID-19 caused far-reaching disruptions in health services, including for HIV treatment and laboratory monitoring. We characterized trends in early ART (eART) and early VS (eVS) among PWH before (2018-2019) vs. during (2020-2021)…

1092 – Mpox Reinfections in California, May 2022 to August 2024

Background At the onset of the 2022 global mpox outbreak, infection from monkeypox virus was believed to offer long-term immunity. However, the first mpox reinfection in California was reported to the California Department Public of Health in April 2023. We sought to identify the frequency of mpox reinfections and associated characteristics to develop clinical and…